Cyrus Biotechnology, Inc., a Seattle-based provider of advanced computational software for protein modeling and design to accelerate new drug discovery, closed an $8M Series A financing.
The round was led by Trinity Ventures, with participation from OrbiMed Advisors, SpringRock Ventures, W Fund and individual investors. In conjunction with the funding, Gus Tai, General Partner at Trinity Ventures, will join the Board of Directors, along with Eric Bell at SpringRock.
Led by CEO Dr. Lucas Nivon, Cyrus offers Bench®, a Software-as-a-Service platform for protein structure prediction, discovery, modeling, stabilization, engineering and design, along with custom software development and experienced scientific support services in computational protein engineering. It accelerates drug discovery at pharmaceutical and biotechnology firms, as well as new product development at synthetic biology, chemical and consumer products firms.
Based on years of work in computational biophysics and the first software algorithms, the company launched a software beta in 2016 with initial release in early 2017, and has acquired customers ranging from Fortune 500 Pharma (including seven of the top 20 pharma firms), chemical and consumer products firms to privately-held biotech and synthetic biology firms.